FDA Discusses Current and Future Take on Compliance - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

FDA Discusses Current and Future Take on Compliance


Pharmaceutical Technology
Volume 35, Issue 1, pp. 42

PharmTech: FDA has been successfully building its overseas presence for a couple of years to help train other national regulatory agencies and to increase inspections of foreign facilities. There is still a lot of grumbling that overseas audits are more lenient than domestic audits (e.g., companies outside of the US have advance notice of inspections, whereas US companies do not). Do you agree with the characterization? What will FDA do to level the playing field?

Friedman: We do not agree with that characterization. Foreign inspections do pose their own unique challenges. FDA only has explicit authority to take legal action on products in its jurisdiction (the United States). Although we do not have authority to seize products in foreign commerce nor enjoin foreign firms, we can administratively block adulterated products from entering the US by placing firms on import alert if we find significant violations during an inspection. This is a faster sanction than seizure or injunction, and is a strong one.

PharmTech: There has been some talk of electronic inspections increasing—including at the ICH workshop in October 2010. Do you see this model growing in the future and if so, what advantages might it offer for industry and for regulators?

Friedman: The inspection of a facility's conditions and practices are done on site. It is analogous to buying a house. You want to see it before you buy it. Indeed, you even do a final walk-through. A manufacturing facility is extremely complex, and CGMP audits require one to observe numerous manufacturing practices like sanitation (such as personal hygiene), state of repair of equipment, whether personnel practices match what is written in SOPs and staff are qualified, contemporaneous completion of batch records, whether operations are being supervised, laboratory conditions and controls, how a firm deals with deviations, etc. With that said, we obtain and leverage electronic information on facility statuses quite routinely these days, particularly when collaborating with our international regulatory counterparts.

PharmTech: Are there any major new guidances affecting drug manufacturing that industry should look for in 2011?

Friedman: We expect FDA's guidance on process validation will publish as final in 2011. In addition, CGMP regulations and guidance for Positron Emission Tomography drugs will go into effect in December 2011. We are also working on other guidances that should enhance industry's understanding of regulatory expectations regarding drug manufacturing and product quality.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
25%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
11%
Regulatory compliance
36%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here